GlassScriptPhysician profile
Brady Bleicher
NPI 1376907394
$9,789.53
in general payments reported to CMS, 2019-2025
32 companies · $491 in 2025
The $491 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $266 · 2021: $721 · 2022: $1,952 · 2023: $2,530 · 2024: $3,545 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,565.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,124.57 | 2021-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $895.25 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $622.12 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $591.08 | 2022-2025 | Adbry |
| Genentech USA, INC. | $519.77 | 2019-2022 | |
| Janssen Biotech, INC. | $495.23 | 2022-2025 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $427.87 | 2022-2025 | |
| Lilly USA, LLC | $390.96 | 2023-2024 | Taltz, Olumiant, Zepbound |
| Ucb, INC. | $364.96 | 2022-2024 | Bimzelx |
| Amgen INC. | $337.01 | 2023-2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $313.42 | 2022-2024 | Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $258.33 | 2021-2024 | Sotyktu |
| Incyte Corporation | $228.58 | 2022-2024 | Opzelura |
| Galderma Laboratories, L.P. | $215.13 | 2021-2025 | Nemluvio, Aklief |
| Pfizer INC. | $208.48 | 2022-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $193.54 | 2022-2025 | Seysara, Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.60 | 2022-2024 | Spevigo |
| Janssen Scientific Affairs, LLC | $121.38 | 2022 | |
| Dermavant Sciences, INC. | $107.51 | 2023 | Vtama |
| Fresenius Kabi USA, LLC | $100.96 | 2023-2024 | Idacio |
| Mayne Pharma Commercial LLC | $88.33 | 2022-2025 | |
| Kyowa Kirin, INC. | $73.73 | 2021-2024 | Poteligeo |
| Arcutis Biotherapeutics, INC. | $66.60 | 2024-2025 | Zoryve |
| Biofrontera INC. | $64.16 | 2023-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Verrica Pharmaceuticals INC. | $62.13 | 2023-2024 | Ycanth |
| Vyne Pharmaceuticals INC. | $53.00 | 2020 | |
| Allergan, INC. | $34.32 | 2022 | |
| Blueprint Medicines Corporation | $29.31 | 2023 | Ayvakit |
| Sandoz INC. | $27.06 | 2024 | Hyrimoz |
| Organon LLC | $25.62 | 2025 | Vtama |
| Lifenet Health | $25.56 | 2023 | |
| Journey Medical Corporation | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brady Bleicher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.